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Introduction: Pralatrexate is an antifolate designed for preferential
tumor cell uptake and accumulation and received accelerated Food
and Drug Administration approval in relapsed/refractory peripheral
T-cell lymphoma. Pralatrexate 135 to 150 mg/m2 every 2 weeks
without vitamin supplementation was active in non-small cell lung
cancer (NSCLC) although mucositis was dose limiting. This phase
1 study evaluated the safety of higher pralatrexate doses with
vitamin supplementation to minimize toxicities.
Methods: Patients with stage IIIB/IV NSCLC received pralatrexate
150 to 325 mg/m2 every 2 weeks with folic acid and vitamin B12
supplementation. Outcomes measured included adverse events
(AEs), pharmacokinetics, and radiologic response.
Results: Thirty-nine patients were treated for a median of two
cycles (range 1–16). Common treatment-related grade 3 and 4
AEs by dose (190 mg/m2 and 190 mg/m2) included mucositis
(33 and 40%) and fatigue (11 and 17%). Treatment-related serious
AE (SAE) rates for doses 190 and 190 mg/m2 were 0 and 20%,
respectively. The response rate was 10% (95% confidence interval:
1–20%), including two patients with complete response (26 and
32 months) and two with partial response. Serum pralatrexate
concentrations increased dose dependently up to 230 mg/m2.
Conclusions: Pralatrexate with vitamin supplementation was safely
administered to patients with previously treated NSCLC, and dura-
ble responses were observed. The recommended starting dose for
phase 2 is 190 mg/m2. A similar safety profile was observed in
patients treated at 230 mg/m2, although a higher serious AE rate was
evident. Mucositis remains the dose-limiting toxicity of pralatrexate,
and this study failed to demonstrate that vitamin supplementation
prevents mucositis and failed to identify clinical predictors of
mucositis. Individualized dose-modification strategies and prospec-
tive mucositis management will be necessary in future trials.
Key Words: Pralatrexate, Antifolate, Non-small cell lung cancer,
NSCLC, Dose-finding.
(J Thorac Oncol. 2011;6: 1915–1922)
Pralatrexate (FOLOTYN Allos Therapeutics, Inc., West-minster, CO) is an antifolate-targeting dihydrofolate re-
ductase (DHFR) and has a high affinity for the reduced folate
carrier (RFC)-1.1 RFC-1 is highly expressed on malignant
tissues and it regulates the internalization of natural folates
required for purine and pyrimidine biosynthesis.2 In lym-
phoma cell lines, RFC-1 gene expression predicted the anti-
tumor activity of pralatrexate,3 and it is hypothesized that the
high affinity of pralatrexate for RFC-1 leads to selective
tumor cell accumulation. Pralatrexate is an efficient substrate
for polyglutamylation by the enzyme folylpolyglutamyl syn-
thetase (FPGS), with activity at FPGS greater than that of
other antifolates (methotrexate, edatrexate, and aminop-
terin).1 The increased uptake and increased polyglutamyla-
tion associated with pralatrexate have been shown to correlate
with increased tumor growth inhibition in non-small cell lung
cancer (NSCLC) xenograft models.4
Pralatrexate recently received accelerated approval by
the U.S. Food and Drug Administration for the treatment of
relapsed or refractory peripheral T-cell lymphoma based on
the results of the PROPEL study.5 Pralatrexate has also been
studied in other types of lymphomas and solid tumors.6 In
particular, several studies have evaluated pralatrexate in pa-
tients with NSCLC as either monotherapy,7,8 or in combina-
tion with taxanes.9 Pralatrexate monotherapy was active at
doses of 135 to 150 mg/m2 every 2 weeks (q2w).7,8 Mucositis
was a common dose-limiting toxicity (DLT), but early mono-
therapy studies did not include administration of vitamin B12
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and folic acid. In the phase 1 study of pralatrexate in com-
bination with a taxane, mucositis was the most common DLT.
Supplementation of vitamin B12 and folic acid in some
patients reduced the incidence of mucositis and allowed the
use of increased doses of pralatrexate.9 In addition, data from
studies of the antifolate pemetrexed (ALIMTA) have led to
the routine administration of vitamin supplementation with
this agent.10 The objective of this phase 1 study (PDX-007)
was to evaluate the safety, tolerability, pharmacokinetic (PK)
profile, and optimal dose of pralatrexate with routine vitamin
B12 and folic acid supplementation in patients with advanced,
previously treated NSCLC.
PATIENTS AND METHODS
Study Design
This was a phase 1, nonrandomized, multicenter, dose-
escalation study. Study participants were 18 years or older
and had stage IIIB or IV NSCLC that was not potentially
curable by standard chemotherapy, radiotherapy, or surgical
procedures. Other inclusion criteria were at least one prior
chemotherapy regimen, Karnofsky Performance Status
70%, life expectancy more than 3 months, and adequate
hematologic, hepatic, and renal function. Key exclusion cri-
teria were previous exposure to pralatrexate, diagnosis of
another active concurrent malignancy, clinically significant
pleural effusion or ascites, grade 3 or 4 edema, prior pneu-
monectomy, recent (within 2 weeks of enrollment) radiation
therapy or chemotherapy (erlotinib or gefitinib within 1 week
before enrollment), symptomatic central nervous system me-
tastases, and other serious medical conditions. The study was
conducted in accordance with the principles contained in the
Declaration of Helsinki and was approved by the Institutional
Review Boards at participating centers. Each patient provided
written informed consent to participate.
Treatment
Each patient received pralatrexate intravenously (IV)
once q2w. Each cycle of therapy was 4 weeks and consisted
of two doses of pralatrexate. Patients received vitamin sup-
plementation starting at least 7 days (day 7) before the first
dose of pralatrexate and continued until discontinuation of
pralatrexate. Vitamin supplementation consisted of vitamin
B12 (1 mg intramuscular every 8 to 10 weeks) and folic acid
(1 mg orally once daily).
Patients were enrolled sequentially into two treatment
groups during the study: treatment group A followed by
group B. treatment group A determined the maximum toler-
ated dose (MTD) of pralatrexate with vitamins based on a
modified, accelerated titration method for dose escalation.11
Treatment group B was a dose de-escalation phase to deter-
mine the recommended phase 2 dose using stricter DLT
criteria. This phase followed a standard 3  3 method of
enrollment into each cohort.
The first dose cohort in treatment group A was 150
mg/m2 q2w by IV bolus (3–5 minutes). If no DLT was
observed in the first patient after one cycle of therapy (two
doses over 4 weeks), the next patient was enrolled at the next
dose level (40 mg/m2 increments until 270 mg/m2 and 20%
increments thereafter). If a DLT was observed in the first
patient, five additional patients were enrolled in the cohort. If
only the first patient in the cohort had a DLT after expansion
to six patients, dose escalation continued to the next level. If
2 patients had a DLT with cohort expansion, dose escala-
tion was stopped, and the MTD was defined as the previously
tolerated dose. After the MTD was identified, the MTD
cohort was expanded to include 16 patients in total to gain
additional safety and tolerability experience at that dose level.
Because several patients in the expanded MTD cohort
had mucositis as DLT at 270mg/m2, additional cohorts were
enrolled into treatment group B to evaluate lower doses. In
addition, grade 2 mucositis was added to the DLT defini-
tion. Another investigation undertaken in treatment group B
was to evaluate the PK and safety profile in patients who
received a protracted infusion (more than 60 minutes) of
pralatrexate. To further evaluate if the safety profile may be
improved using a longer infusion, subsequent cohorts in
treatment group B received pralatrexate 230 mg/m2 q2w by
IV bolus, prolonged infusions, and/or lower doses of prala-
trexate (40 mg/m2 reductions).
Treatment was delayed in patients with active mucosi-
tis. Those patients who experienced grade 3 mucositis re-
started pralatrexate at a 40% reduced dose after mucositis
resolved. There was no change in dose for other nonhemato-
logic grade 0 to 2 adverse events (AEs). The dose was
delayed for 2 weeks in patients with other grade 3 nonhema-
tologic treatment-related AEs and restarted as follows: if the
AE resolved to grades 0 and 1, treatment was restarted at the
same dose; if resolved to grade 2, treatment was restarted
with a 20% dose reduction; if grade 3 persisted, the next dose
was omitted. Pralatrexate treatment was discontinued for any
grade 4 treatment-related nonhematologic AE. For treatment-
related hematologic AEs, pralatrexate treatment was delayed
in patients with grade 2 neutropenia and grade 2 thrombocy-
topenia. Treatment was delayed and could be restarted at a
20% reduced dose in patients with grade 3 neutropenia with
fever or grade 4 neutropenia upon recovery. Prophylactic use
of hematopoietic growth factors during cycle 1 was not
permitted.
Assessments
Investigators recorded each AE including its relation-
ship to pralatrexate treatment and its severity according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events scale, Version 3.0. Blood samples were
tested for red blood cell (RBC) folate, homocysteine (HC),
and methylmalonic acid (MMA) levels at enrollment, before
the first dose of pralatrexate, and after cycle 1 as a measure of
vitamin deficiency and to measure the impact of vitamin
supplementation. Serial PK plasma and urine samples were
collected for 72 hours after the first dose of pralatrexate.
Additional PK plasma samples were collected for 20 minutes
after the second dose. If specimens were available, formalin-
fixed paraffin-embedded (FFPE) tumor tissue was collected
as part of the treatment initiation visit. Available FFPE tissue
was tested for components of folate metabolism (RFC-1,
DHFR, FPGS, thymidylate synthase [TS], glycinamide ribo-
nucleotide formyltransferase, and gamma-glutamyl hydro-
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lase) to identify biomarkers that may correlate with drug
activity. The relative gene expression of RFC-1, DHFR,
FPGS, TS, glycinamide ribonucleotide formyltransferase,
and gamma-glutamyl hydrolase was evaluated using a reverse
transcription polymerase chain reaction assay using standard
techniques (Response Genetics, Inc., Los Angeles, CA).
Investigators evaluated radiologic response using serial
computed tomography scans and tumor measurements. Treat-
ment response was categorized using RECIST.12 Responders
continued to be followed for duration of response after the
safety analyses were completed.
Dose-Limiting Toxicity
The definition of DLT in group A included the follow-
ing: (1) grade 3 treatment-related hematologic toxicity,
excluding anemia, lasting for 7 days or requiring treatment
with filgrastim or pegfilgrastim; (2) grade 3 neutropenia
with fever; (3) grade 3 treatment-related nonhematologic
toxicity, excluding nausea and vomiting; and (4) dose delay
of more than 2 weeks for treatment-related toxicity. In group
B, grade 2 mucositis was added as a DLT to determine the
recommended phase 2 dose.
Statistical Analysis
Data were analyzed for all patients who were enrolled
and received at least one dose of pralatrexate. Baseline values
and outcomes were summarized by treatment cohort.
RESULTS
Study Population
The 39 patients who received at least one dose of
pralatrexate comprised the efficacy and safety population.
Baseline characteristics of these 39 patients are summarized
in Table 1. Of these, 29 discontinued the study for progres-
sive disease, 1 because of withdrawal of consent, 6 because of
AEs, and 1 because of the development of an AE that resulted
in more than one dose reduction of pralatrexate. At the time
of reporting this article, two patients remained on study with
sustained complete radiologic responses (26 months and
32 months).
The number of patients who received 150, 190, 230,
270, and 325 mg/m2 was 1, 8, 11, 16, and 3, respectively,
across both treatment groups. Of the 39 patients treated with
pralatrexate, 29 received bolus injections over 3 to 5 minutes
and 10 (5 each in the 190 and 230 mg/m2 cohorts in treatment
group B) received 1-hour infusions. Most patients (87%)
were white and 59% were women. The mean age was 61
years. Although all histological subtypes were included in
eligibility criteria, the majority (82%) were adenocarcinomas.
Fifteen patients (38%) received one prior chemotherapy reg-
imen, 7 (18%) received two prior, and 17 (44%) patients
received three or more. The most commonly used prior
chemotherapy regimens were platinum-based combinations
(92%). Fourteen patients (36%) received prior pemetrexed,
and prior treatment with epidermal growth factor receptor
therapy (59%) was also permitted. Nineteen patients (49%)
received prior radiation, four patients received surgical resec-
tion for early-stage or metastatic NSCLC before being en-
rolled on the study with progressive NSCLC.
Pralatrexate Dosing
Patients received pralatrexate for a median of two
cycles (range 1–16). The mean number of doses in the 150,
190, 230, 270, and 325 mg/m2 cohorts was 4.0, 4.4, 6.7, 7.5,
TABLE 1. Baseline Patient Characteristics
Value
150 mg/m2
(n  1)
190 mg/m2
(n  8)
230 mg/m2
(n  11)
270 mg/m2
(n  16)
325 mg/m2
(n  3)
Total
(n  39)
Female, n (%) 1 (100) 4 (50) 5 (45) 12 (75) 1 (33) 23 (59)
Race, n (%)
White 1 (100) 5 (63) 10 (91) 15 (94) 3 (100) 34 (87)
Black 0 (0) 3 (38) 1 (9) 1 (6) 0 (0) 5 (13)
Age (yr)
65, n (%) 0 (0) 4 (50) 5 (45) 6 (38) 0 (0) 15 (38)
Mean (SD) 54.0 (—) 64.5 (10.4) 62.1 (10.5) 60.7 (7.9) 55.3 (7.1) 61.3 (9.1)
Adenocarcinoma 1 (100) 5 (63) 10 (91) 15 (94) 1 (33) 32 (82)
Squamous cell 0 (0) 2 (25) 0 (0) 0 (0) 1 (33) 3 (8)
Other histology 0 (0) 1 (12) 1 (9) 1 (6) 1 (33) 4 (10)
Prior therapy, n (%)
Chemotherapy 1 (100) 8 (100) 11 (100) 16 (100) 3 (100) 39 (100)
Radiation 1 (100) 4 (50) 4 (36) 9 (56) 1 (33) 19 (49)
Resection 0 (0) 0 (0) 0 (0) 3 (19) 1 (33) 4 (10)
Other 0 (0) 3 (38) 7 (64) 11 (69) 1 (33) 22 (56)
No. of prior NSCLC
chemotherapy regimens
1 1 (100) 4 (50) 4 (36) 5 (31) 1 (33) 15 (38)
2 0 (0) 1 (13) 1 (9) 4 (25) 1 (33) 7 (18)
3 0 (0) 3 (38) 6 (55) 7 (44) 1 (33) 17 (44)
NSCLC, non-small cell lung cancer.
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and 4.7, respectively, and the mean duration of pralatrexate
treatment was 1.4, 1.8, 2.8, 3.5, and 1.8 months, respectively.
Two patients (1 each in the 230 and 270 mg/m2 cohorts)
were still in response and receiving treatment at the time of
data cutoff. The maximum number of cycles initiated in
the 150, 190, 230, 270, and 325 mg/m2 cohorts were 2, 7,
15, 16, and 4, respectively, and the mean cumulative
pralatrexate dose was 596, 710, 1471, 1646, and 1194
mg/m2, respectively.
Seventeen patients had dose reductions because of AEs,
of which 14 were due to mucositis (0, 63, 9, 38, and 67% of
patients in the 150, 190, 230, 270, and 325 mg/m2 cohorts,
respectively) and 1 each because of fatigue (230 mg/m2),
hand-foot syndrome (270 mg/m2), and high alanine amino-
transferase levels (270 mg/m2).
Safety
Dose levels and DLTs are summarized for group A in
Table 2. Of these patients, one of six patients in the 270
mg/m2 cohort and two of three patients in the 325 mg/m2
cohort had DLTs, and the MTD was determined to be 270
mg/m2. When 10 additional patients were enrolled into the
initial MTD cohort (270 mg/m2), four of these patients had
mucositis as a DLT under the original definition for nonhe-
matologic toxicity (i.e., grade 3 mucositis).
After this experience, patients were enrolled into four
lower dose cohorts distinguished by dose and duration of
infusion. These patients are listed in Table 2 as group B. At
the conclusion of the study, 6 of 11 patients treated at 230
mg/m2 (groups A  B) had grade 2 (four patients) or three
(two patients) mucositis, including one patient who had
coincident grade 3 neutropenia and thrombocytopenia. Four
of eight patients treated at 190 mg/m2 (groups A  B) had
grade 2 (two patients) or 3 (two patients) mucositis. There
were no dose-limiting cytopenias at this dose. There was no
significant difference in rate of mucositis between patients in
group B treated with bolus, versus 1-hour infusion of prala-
trexate.
Most patients (97%) experienced at least one AE during
the study (Table 3). The most common AEs, grades 1 to 4 and
regardless of causality, were mucositis (79%), fatigue (67%),
nausea (44%), and epistaxis (28%). Most AEs were grades 1
and 2 in severity. The most common grade 3 and 4 treatment-
related AEs by dose (190 mg/m2 and 190 mg/m2) were
oral mucositis (33 and 40%) and fatigue (11 and 17%).
Patients in the 150 and 190 mg/m2 cohorts had no grade 3 and
4 hematologic AEs and no grade 4 nonhematologic AEs.
Most patients (95%) experienced at least one AE that
the investigator considered related to pralatrexate. The most
common treatment-related AEs were oral mucositis (stoma-
titis; 69%), fatigue (67%), nausea (38%), and epistaxis
(26%). Notably, at doses 190 mg/m2 there were no treat-
ment-related serious adverse events (SAEs). Six patients
(20%) had SAEs at doses more than 190 mg/m2: five cases of
mucositis and one case of headache, all events resolved. One
patient died of progressive disease that was not considered
related to treatment. No patient had a grade 4 hematologic AE
or a grade 4 change in any laboratory value. Grade 3 anemia,
grade 3 thrombocytopenia and neutropenia, grade 3 elevation
of alanine aminotransferase, and grade 3 hypokalemia oc-
curred in one patient each.
Treatment Response
The overall response rate (ORR) by RECIST was 10%
(4/39; 95% confidence interval [CI]: 1–20%), summarized in
Table 4. Responses included two patients (5%) with complete
response (CR), both of whom were still receiving pralatrexate
at the time of this report (time on treatment 26 and 32
months, respectively). Of the other two patients (5%) who
responded, one patient had a partial response (PR) for 10
months and one patient with PR at the primary site developed
leptomeningeal disease at 2 months. The responders were
TABLE 2. Dose Levels and Dose-Limiting Toxicity
Cohort
No. of
Patients
Dose
(mg/m2)
Bolus (3–5 min)
or Infusion (60 min) Dose-Limiting Toxicity
A1 1 150 Bolus —
A2 1 190 Bolus —
A3 1 230 Bolus —
A4 6 270 Bolus 1 Mucositis (Gr 3)
A5 3 325 Bolus 2 Mucositis (Gr 3)
A4 (expansion) 10 270 Bolus 2 Mucositis (Gr 3)
1 Mucositis  fatigue (Gr 3  3)
1 Mucositis  fatigue  headache (Gr 3  3  3)
B1 5 230 Bolus 3 Mucositis (Gr 2)
1 Mucositis (Gr 2–3)
B2 5 230 Infusion 1 Mucositis (Gr 3)
1 Mucositis  thrombocytopenia  neutropenia (Gr 2  3  3)
B3 2 190 Bolus 2 Mucositis (Gr 3)
B4 5 190 Infusion 2 Mucositis (Gr 2)
The maximum tolerated dose in part A was identified as 270 mg/m2 because of dose-limiting toxicities in two of three patients at 325 mg/m2; 10 additional
patients were enrolled to the 270 mg/m2 dose in the “expansion” cohort, and 4 of 10 had dose-limiting toxicities. Part B evaluated lower doses (230 and 190
mg/m2) and extended 1-h infusions; grade 2 mucositis was added as a dose-limiting toxicity in part B only.
Gr, grade.
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treated at initial doses of 270 mg/m2 (CR), 270 mg/m2 (PR),
230 mg/m2 (CR), and 150 mg/m2 (PR), all four had adeno-
carcinoma, and three had received three or more prior che-
motherapy regimens. A waterfall plot summarizing the max-
imum percent change in tumor size from baseline and dose
level for all 39 patients who received pralatrexate is provided
(Figure 1).
Twenty-six patients (67%) had best response of stable
disease (SD) including 16 (41%) for more than 2 months. The
resulting disease control rate (ORR  SD for 2 months)
was 51% (20/39; 95% CI: 36–67%), and the rate of SD or
better was 77% (30/39; 95% CI: 34–90%) (Table 4).
Pharmacokinetics
The PK profile for racemic pralatrexate is summarized
by cohort in Table 5. With both administration schedules,
mean values for Cmax increased dose dependently and were
approximately three-fold higher with the 3- to 5-minute bolus
than with the 60-minute infusion. With both dosing sched-
ules, mean values for area under the curve (AUC) increased
dose dependently up to 230 mg/m2 and then appeared to
plateau. Other PK parameters, including clearance, volume of
distribution, half-life, and fraction excreted in urine, were
independent of dose or schedule. The mean plasma concen-
tration-time profile for racemic pralatrexate after the first dose
also was similar between dose cohorts (Figure 2).
Potential Predictors of Toxicity
No predictors of toxicity were identified in this study other
than dose. There was no correlation between patient experience
of mucositis and number of prior chemotherapies, baseline
vitamin deficiency as measured by RBC folate, HC, MMA, or
TABLE 3. Grades 3 and 4 Adverse Events
Grades 3 and 4 Event,
n (%)
150 mg/m2
(n  1)
190 mg/m2
(n  8)
230 mg/m2
(n  11)
270 mg/m2
(n  16)
325 mg/m2
(n  3)
Gr3 Gr4 Gr3 Gr4 Gr3 Gr4 Gr3 Gr4 Gr3 Gr4
Any grades 3 and 4 event 0 0 4 (50) 0 6 (55) 1 (9) 9 (56) 1 (6) 2 (67) 0
Hematologic
Anemia 0 0 0 0 1 (9) 0 0 0 0 0
Neutropenia 0 0 0 0 1 (9) 0 0 0 0 0
Thrombocytopenia 0 0 0 0 1 (9) 0 0 0 0 0
Nonhematologic
Mucositisa 0 0 3 (38) 0 2 (18) 1 (9) 6 (38) 0 2 (67) 0
Fatigue 0 0 2 (25) 0 1 (9) 0 4 (25) 0 0 0
Dyspnea 0 0 1 (13) 0 1 (9) 0 0 1 (6) 0 0
Back pain 0 0 0 0 0 0 2 (13) 0 0 0
Dehydration 0 0 0 0 0 0 1 (6) 0 0 0
Headache 0 0 0 0 0 0 1 (6) 0 0 0
Hypoxia 0 0 0 0 1 (9) 0 0 0 0 0
LFT abnormal 0 0 0 0 0 0 1 (6) 0 0 0
Malaise 0 0 0 0 0 0 1 (6) 0 0 0
Noncardiac chest pain 0 0 0 0 0 0 1 (6) 0 0 0
Odynophagiaa 0 0 0 0 0 0 1 (6) 0 0 0
Pain in extremity 0 0 0 0 1 (9) 0 0 0 0 0
Hand-foot syndrome 0 0 0 0 0 0 1 (6) 0 0 0
Pleural effusion 0 0 0 0 0 0 1 (6) 0 0 0
Pulmonary obstruction 0 0 0 0 0 0 1 (6) 0 0 0
Small intestine obstruction 0 0 0 0 0 0 1 (6) 0 0 0
Somnolence 0 0 0 0 1 (9) 0 0 0 0 0
Syncope 0 0 0 0 1 (9) 0 0 0 0 0
Bolus and infusion cohorts had similar toxicities so were combined for 190 and 230 mg/m2 in this table.
a Similar terms were grouped (i.e., “stomatitis” and “mucosal inflammation” for mucositis).
LFT, liver function test.
TABLE 4. Treatment Response
Response Evaluable (n  39)
RECIST response, no. (%)
CR 2 (5)
PR 2 (5)a
SD 2 mo 16 (41)
SD 2 mo 10 (26)
PD 9 (23)
Summary rates, no. (%)
Overall response rate (CR or PR) 4 (10)
Disease control rate (CR, PR, or SD  2 mo) 20 (51)
Stable disease or better (CR/PR/SD) 30 (77)
a One patient with partial response at the primary site developed leptomeningeal
disease at 2 mo.
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease.
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PK parameters (Cmax or AUC) within each dose level. Vitamin
B12 and folic acid supplementation initiated at least 7 days
before initiation of pralatrexate improved vitamin status in pa-
tients. RBC folate increased from a median of 738 to 764 ng/ml,
MMA decreased from a median of 186 to 164 nmol/liter, and
HC decreased from a median of 10.5 to 9.l mol/liter before the
first dose of pralatrexate. Although the MTD of pralatrexate was
found to be higher in this study with the use of vitamin supple-
mentation, the overall rate of mucositis (any grade) was similar
in patients treated at doses 190 mg/m2 and 190 mg/m2.
High-grade mucositis resulting in a serious AE was more likely,
and there was a higher rate of treatment-related SAEs and
myelosuppression at doses more than 190 mg/m2.
DISCUSSION
Biweekly administration of pralatrexate with vitamin
supplementation was safe in patients with previously treated,
advanced NSCLC. As in the previous studies of pralatrexate
without vitamin supplementation,7–9 oral mucositis remained
the most common DLT. Other AEs were consistent with
those in previous studies of pralatrexate in NSCLC, and most
events were mild and reversible. There were no treatment-
related serious AEs, grade 3 and 4 hematologic AEs, or grade
4 nonhematologic AEs recorded in patients treated at doses
190 mg/m2. Rates of any grade and grades 3 and 4 mucosi-
tis were similar at doses 190 mg/m2 and 190 mg/m2.
Results from the safety analysis indicated 190 mg/m2,
along with vitamin supplementation, to be the optimal start-
ing dose. This dose is higher than the MTD in the prior phase
1 and phase 2 studies that did not include vitamin supple-
mentation (170 and 135 mg/m2 q2w, respectively).6,7 With
pralatrexate delivered at a dose of 190 mg/m2 IV q2w,
mucositis remains the DLT, and this study failed to demon-
strate that vitamin supplementation prevents mucositis. Be-
FIGURE 1. Maximum percent change
in tumor size from baseline (radiographic
only). The dose level of each responder is
provided.
TABLE 5. Pharmacokinetic Profile, Racemic Pralatrexate
Cohort
Mean Value
n
Cmax
(ng/ml)
AUC
(ng/ml min)
CLtot
(ml/min)
Vdss
(liter)
t1/2
(min)
fe
(%)
Overall 37 52,712 1,832,138 361 75 1280 29
150 mg/m2 bolus 1 24,729 551,967 601 356 4080 24
190 mg/m2 bolus 3 28,141 1,290,391 351 63 869 20
230 mg/m2 bolus 4a 55,931 2,082,075 242 63 1941 35
270 mg/m2 bolus 16 64,050 1,792,341 329 52 1187 28
325 mg/m2 bolus 3 66,155 2,167,199 474 182 2699 30
190 mg/m2 infusion 5 10,771 1,200,685 489 67 485 32
230 mg/m2 infusion 5 17,192 1,853,588 346 57 545 34
a One outlier was removed for Cmax and AUC calculation.
Cmax, maximum concentration; AUC, area under the concentration-time curve from time 0 to infinity; CLtot, total clearance; Vdss,
volume of distribution at steady state; t1/2, terminal half-life; fe, fraction excreted in urine.
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fore publication of this phase 1 study, the results of a phase
2 study which delivered pralatrexate plus vitamins at a
median dose of 190 mg/m2 to 100 patients with previously-
treated metastatic NSCLC were reported in an abstract. In the
phase 2 study, rates of mucositis were 34% grade 2, 20%
grade 3, and 3% grade 4, and 21% of patients discontinued
pralatrexate because of mucositis, the majority of which
occurred during cycle 1.13
In this phase 1 study, the additional toxicities encoun-
tered during planned expansion of the cohort at the initial
MTD (270 mg/m2) highlight the importance of cohort expan-
sion in phase 1 trials to account for patient heterogeneity. One
could argue that smaller dose increments might have allowed
discovery of intermediate dose levels with less toxicity.
However, in this study, as in prior phase 1 and 2 studies of
pralatrexate, no clinical predictive factors for the develop-
ment or severity of mucositis were identified. Until such
discoveries are made, future pralatrexate clinical trials should
include individualized treatment modification and prospec-
tive mucositis management strategies to maximize pralatrex-
ate exposure and maintain tolerability.
The PK evaluations in this phase 1 study were consis-
tent with those reported previously without vitamin supple-
mentation in patients with NSCLC,7 suggesting that the
addition of vitamin supplementation did not significantly alter
the PK profile. Within this study, the PK profiles of bolus and
1-hour infusion dosing were similar, aside from expected
differences in Cmax. The AUC of pralatrexate increased dose
dependently with both administration schedules but appeared
to reach a plateau at 230 mg/m2. There was no significant
difference in rates of mucositis when pralatrexate was admin-
istered as a bolus versus 1-hour infusion.
Pralatrexate therapy was associated with durable CR in
two patients (26 and 32months) and PR in two additional
patients (10 and 2 months) for an ORR of 10%. Several other
patients had SD, including prolonged SD for more than 2
months in 41% and 2 months in 26%, thus resulting in
disease control in approximately one half of patients (51%)
and SD or better in most patients (77%). Of note, duration of
response in the two patients with recurrent NSCLC treated
with pralatrexate (26 and 32 months) is longer than the
median survival (8 months) of patients in this population.14
Long duration of response was also observed with pralatrex-
ate in relapsed/refractory peripheral T-cell lymphoma.5
Previous studies reported objective treatment re-
sponses with single-agent pralatrexate at doses of 150 to
170 mg/m2 q2w7,8 or the combination of a taxane plus
pralatrexate 60 to 110 mg/m2 q2w (without vitamin sup-
plementation) or 80 to 140 mg/m2 (with vitamin supple-
mentation).9 In this trial, clinical activity was evident at
doses of 150 mg/m2 and higher.
Because of a small number of tissue samples, mean-
ingful correlation between biomarker results and safety or
treatment response could not be evaluated. FFPE tumor tissue
was available in sufficient quantity for gene expression anal-
ysis in only six patients, and most samples represented
primary tumor removed at surgery and not contemporary with
chemotherapy for metastatic disease.
In this study, all of the patients observed to have major
radiologic responses had adenocarcinoma histology. Simi-
larly, in the phase 2 study of pralatrexate recently reported,
there were trends to greater efficacy with pralatrexate in
patients with nonsquamous histology and (not surprisingly) in
patients who did not stop taking pralatrexate on account of
mucositis.13 Another antifolate drug for NSCLC, pemetrexed,
has also been observed to be more effective in patients with
nonsquamous histology.15 Pralatrexate targets primarily
DHFR, whereas pemetrexed targets primarily TS. The bio-
logical mechanisms behind these parallel observations have
yet to be elucidated.
In conclusion, pralatrexate in combination with vitamin
B12 and folic acid was safe in patients with previously treated
NSCLC, and durable responses were observed. Oral mucosi-
tis remained the DLT, but higher doses than previous trials
were tolerated most likely because of vitamin supplementa-
tion. Observations in this study, and other phase 2 studies in
NSCLC, show trends for improved efficacy in nonsquamous
histology. However, molecular markers for selection of pa-
tients more likely to benefit from pralatrexate have yet to be
elucidated. Future pralatrexate clinical trials should include
individualized treatment modification and prospective mu-
cositis management strategies to maximize pralatrexate ex-
posure and maintain tolerability.
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FIGURE 2. A and B, Mean plasma concentration-time profile on day 1 (0–80 hours), racemic pralatrexate.
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